Market Context — Why This Technology, Why Now

The escalating global burden of chronic skin conditions, exacerbated by environmental factors and an aging demographic, is driving an urgent demand for innovative dermatological solutions. Patients and healthcare providers are increasingly seeking treatments that offer not just symptom relief but also improved safety profiles and long-term efficacy. This patent's novel mechanism for pruritus aligns perfectly with this trend, offering a potential breakthrough in a market where existing therapies often fall short, creating a significant opportunity for market disruption and leadership.

Key Competitive Advantages
01

Targets a novel neurotransmitter and receptor for itch, offering a fundamental therapeutic effect beyond existing symptomatic treatments.

02

Targets specific receptors, potentially reducing systemic side effect risks and avoiding common issues like drowsiness or dry mouth associated with current medications.

03

The patent, protected until February 2038, enables market exclusivity for a novel mechanism-of-action therapy, establishing a stable revenue base.

Market Opportunity
Chronic Pruritic Skin Disease Therapeutics
$3.0B–$3.5B (domestic, AI est.)
The increasing aging population and prevalence of lifestyle diseases are driving a rise in patients suffering from chronic itch. Given the limitations of existing medications, there is high anticipation for novel mechanisms of action.
Dermatology pharmaceutical companies Specialty pharma focused on chronic conditions Biotech firms developing novel pain/itch pathways
Atopic Dermatitis Therapeutics
$1.5B–$2.0B (domestic, AI est.)
This technology could serve as an adjunct or alternative to existing treatments for pruritus, a primary symptom of atopic dermatitis, contributing to market expansion.
Large pharmaceutical companies with dermatology portfolios Biologics developers for inflammatory skin conditions Medical device companies for skin health
Neuropathic Pruritus Therapeutics
$600M–$700M (domestic, AI est.)
Neuropathic pruritus, caused by abnormal neural pathways, is difficult to treat. This technology's action on neurotransmitters could offer a specific therapeutic approach.
Neuroscience-focused pharmaceutical companies Pain management drug developers Orphan drug developers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a novel therapeutic method for pruritic skin diseases, specifically targeting a new neurotransmission mechanism using CCK-2 receptor antagonists. It is considered robust, having overcome two office actions and distinguishing itself from seven prior art documents, thus establishing a strong, low-invalidation-risk right.

Competitive White Space

This patent primarily covers the therapeutic agent and its mechanism. White space exists in developing novel diagnostic tools for specific itch pathways, advanced drug delivery systems for the active compounds, or exploring combination therapies with existing dermatological treatments.

Economic Impact
~$65M/year estimated annual revenue potential (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Based on a domestic pruritic skin disease market of ~$3.5B (AI est.), capturing a 5% share as a novel therapeutic could generate ~$150M (AI est.) in annual revenue. Targeting refractory patients with insufficient response to existing treatments could yield over ~$65M (AI est.) in annual sales, alongside significant non-monetary value from improved patient quality of life.

Speed to Market
3× faster than in-house development
This technology's strength lies in identifying a novel neurotransmission mechanism causing pruritus and discovering existing CCK-2 receptor antagonists as active ingredients. Since this foundational research and candidate substance identification are complete, the initial drug discovery phase, which typically takes several years, can be significantly shortened, enabling an earlier transition to clinical development. This offers the potential for market entry approximately 7 years faster than starting in-house R&D from scratch.
Competitive Positioning

X: Curative Treatment Efficacy
Y: Reduced Side Effect Risk

Business Models & Applications
💊 Pharmaceutical Development & Sales
Develop this technology into a novel therapeutic, proceeding through clinical trials to gain regulatory approval. Revenue could be generated through direct sales or by licensing to major pharmaceutical companies.
🍎 Functional Foods & Supplements
Parallel to pharmaceutical development, focus on low-dose itch-relief effects. This model involves launching the technology as a functional food or supplement, offering a preventative approach to the market.
🐶 Veterinary Medicine Development
Skin diseases, especially pruritus, are common issues in pets. This technology could be developed into a veterinary medicine for animals like dogs and cats, entering the growing animal health market.
Adjacent Application Opportunities
🏥 Medical Devices & Diagnostics
Pruritus Severity Measurement Device
Applying the mechanism of action from this technology, a device could be developed to objectively quantify pruritus, aiding in visualizing treatment efficacy and early diagnosis. This would allow for the quantification of patient symptoms to optimize treatment plans in a market segment estimated at over $1B globally.
🧪 Cosmetics & Functional Ingredients
Sensitive Skin Care Products
Leveraging insights from this technology, functional ingredients with itch-suppressing effects could be incorporated into skincare products and bath additives for sensitive or dry skin. This offers a non-pharmaceutical approach to improve skin conditions for a broad consumer base, potentially tapping into a $10B+ global market for sensitive skin care.
🔬 Research Reagents & Tools
Novel Drug Screening Platform
The CCK-2 receptor-related compounds and mechanisms identified by this technology could be offered as research reagents, contributing to the discovery of new anti-pruritic drugs and disease mechanism elucidation. This platform could accelerate drug discovery research, providing value to universities and pharmaceutical companies, with the global research reagents market valued at over $20B annually.
Integration Roadmap — Estimated 36-Month Deployment
Basic Research & Preclinical Evaluation
Duration: 6 months
Optimize the active ingredients of this technology and acquire further in vitro/in vivo safety and efficacy data, along with pharmacokinetic evaluations.
Clinical Development & Trial Planning
Duration: 12 months
Develop clinical trial plans through discussions with regulatory authorities, proceed with investigational drug manufacturing, and prepare for and initiate Phase I/II clinical trials. Further characterize candidate substances.
Regulatory Approval & Market Launch
Duration: 18 months
Conduct data analysis post-clinical trials, prepare and submit regulatory approval documents, and develop and execute marketing and distribution strategies for market launch.
Technical Feasibility
This technology identifies a novel itch transmission mechanism and has already identified existing compound groups that inhibit its action as active ingredients. With this established foundational biological knowledge, the initial drug discovery phase can be significantly shortened, providing a technical basis that can be integrated relatively smoothly into existing pharmaceutical development processes. This is expected to reduce development risks and timelines.
Success Scenario
Adopting this technology could enable companies to add a groundbreaking, novel mechanism-of-action therapeutic candidate for pruritus to their existing drug development pipelines. This could provide new treatment options for patients suffering from refractory pruritus and establish market leadership in the highly competitive dermatology sector. Ultimately, this is expected to enhance corporate brand value and secure long-term revenue streams.
Patent Record
APPLICATION NO.
JP2018-568647
REGISTRATION NO.
7144052
FILING DATE
2018/02/19
GRANT DATE
2022/09/20
EXPIRATION DATE
2038/02/19
PATENT HOLDER
学校法人順天堂
Examination History
2021-02-17
Request for Examination
2022-02-15
Office Action
2022-03-24
Amendment (Voluntary)
2022-03-24
Applicant's Response
2022-07-05
Office Action
2022-08-10
Amendment (Voluntary)
2022-08-10
Applicant's Response
2022-09-06
Decision to Grant